Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Uveal Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Psoriasis 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Follicular 1Dermatitis 1

Interventions

pembrolizumab 7Ipilimumab 7Nivolumab 5Melphalan 5Dacarbazine 3tebentafusp 2sotrastaurin 2binimetinib 2Pemetrexed 2Crizotinib 2ADI PEG20 2utomilumab 1trametinib 1tocilizumab 1siremadlin 1ruxolitinib 1relatlimab 1obinutuzumab 1fludarabine phosphate 1fludarabine 1cemiplimab 1avelumab 1Watchful Waiting 1Toll-Like Receptor 1 1Standard of Care 1Solutions 1Rose Bengal 1Protein Kinase C 1Polyethylene Glycols 1Opdualag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Uveal Melanoma × sotrastaurin × Clear all
NCT01430416 2020-12-19

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Novartis

Phase 1 Completed
153 enrolled
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT01801358 2020-09-16

A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

Array BioPharma

Phase 1/2 Terminated
38 enrolled 31 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡